Sign In
Buy VIVO
$5.74
-0.620 (-9.75%)
At Close: Jun 03, 2026
Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference
01:13pm, Monday, 23'rd May 2022
CINCINNATI , May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today its part
3 Red-Hot Stocks That Could Continue to Beat the Market
11:20am, Thursday, 12'th May 2022 The Motley Fool
These three companies are among the few that have seen their shares rise so far this year.
3 Red-Hot Stocks That Could Continue to Beat the Market
07:20am, Thursday, 12'th May 2022
These three companies are among the few that have seen their shares rise so far this year.
Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History
03:15pm, Friday, 06'th May 2022
Meridian Bioscience Inc (NASDAQ: VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segments ahead of expectations, beating the consensus of
Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q2 2022 Results - Earnings Call Transcript
01:25pm, Friday, 06'th May 2022
Meridian Bioscience, Inc. (NASDAQ:VIVO ) Q2 2022 Earnings Conference Call May 6, 2022 10:00 AM ET Corporate Participants Charlie Wood - Vice President of Investor Relations Jack Kenny - Chief Executiv
Meridian Bioscience (VIVO) Q2 Earnings and Revenues Surpass Estimates
01:15pm, Friday, 06'th May 2022 Zacks Investment Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 37.50% and 11.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Q2 Earnings and Revenues Top Estimates
11:15pm, Thursday, 05'th May 2022 Zacks Investment Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 43.75% and 2.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Computer Programs and Systems (CPSI) Outpaced Other Medical Stocks This Year?
01:40pm, Thursday, 05'th May 2022 Zacks Investment Research
Here is how Computer Programs and Systems (CPSI) and Meridian Bioscience (VIVO) have performed compared to their sector so far this year.
Why Earnings Season Could Be Great for Meridian Bioscience (VIVO)
01:00pm, Thursday, 05'th May 2022 Zacks Investment Research
Meridian Bioscience (VIVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Meridian Bioscience (VIVO) is on the Move, Here's Why the Trend Could be Sustainable
12:50pm, Thursday, 05'th May 2022 Zacks Investment Research
Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed th
Meridian Bioscience (VIVO) is on the Move, Here's Why the Trend Could be Sustainable
10:33am, Thursday, 05'th May 2022
Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed th
Why Earnings Season Could Be Great for Meridian Bioscience (VIVO)
10:32am, Thursday, 05'th May 2022
Meridian Bioscience (VIVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Nephros Inc. (NEPH) Reports Q1 Loss, Misses Revenue Estimates
12:05am, Thursday, 05'th May 2022 Zacks Investment Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of -53.85% and 25.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
What Awaits Meridian Bioscience (VIVO) This Earnings Season?
02:47pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Meridian Bioscience's (VIVO) fiscal second-quarter results are likely to reflect continued strength across both its segments.
What Awaits Meridian Bioscience (VIVO) This Earnings Season?
12:02pm, Tuesday, 03'rd May 2022
Meridian Bioscience's (VIVO) fiscal second-quarter results are likely to reflect continued strength across both its segments.
